Skip to content
drillr.ai
Sign up

OCS

Oculis Holding AG

NASDAQ · Healthcare · Biotechnology · CH

$7.28
−4.59%
Ask drillr

  • Nov 4, 2026, 01:56 UTC

    Oculis Holding AG reported a quarterly loss of $0.37 per share, compared with a Zacks Investment Research, Inc. consensus estimate of a $0.49 loss and a $0.40 loss per share a year earlier.

    Source:

  • Nov 3, 2026, 21:05 UTC

    Oculis Holding AG announced its financial results for the third quarter ended September 30, 2026.

    Source:

  • Oct 22, 2026, 06:00 UTC

    Oculis Holding AG reported Phase 2 ACUITY biomarker data showing that privosegtor reduced post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein compared with placebo.

    Source:

  • Oct 19, 2026, 06:00 UTC

    Oculis Holding AG completed randomization in the PREDICT-1 registrational trial of licaminlimab, with 176 patients enrolled and two-thirds carrying the TNFR1 genetic variant targeted for enrichment.

    Source:

  • Oct 7, 2026, 06:00 UTC

    Oculis Holding AG announced plans to highlight licaminlimab at Eyecelerator @ AAO 2026 and partner with Neuro-Ophthalmology Subspecialty Day.

    Source:

  • Oct 1, 2026, 06:00 UTC

    Oculis joined the National Multiple Sclerosis Society's campaign to end MS, aligning with the campaign's goal to accelerate MS research breakthroughs and improve patients' quality of life.

    Source:

  • Sep 17, 2026, 20:05 UTC

    A member of Oculis Holding AG's Board of Directors purchased ordinary shares of the company, as disclosed in a notification published on September 17, 2026.

    Source:

  • Aug 24, 2026, 08:00 UTC

    Oculis Holding AG announced that the first patient has been treated in the PIONEER-1 registrational trial of Privosegtor for optic neuritis.

    Source:

  • Aug 10, 2026, 07:01 UTC

    Oculis Holding AG signed an asset purchase agreement with Accure Therapeutics to acquire all worldwide development and commercial rights to Privosegtor, terminating their existing license agreement.

    Source:

  • Aug 6, 2026, 20:05 UTC

    Oculis Holding AG reported its financial results for the second quarter ended June 30, 2026.

    Source:

  • Jun 9, 2026, 08:00 UTC

    Oculis Holding AG randomized the first patient in the PREDICT-1 registrational trial of Licaminlimab for dry eye disease.

    Source:

  • May 31, 2026, 21:05 UTC

    Oculis shelves FDA filing for OCS-01 in diabetic macular edema after Phase 3 trials miss key vision goals.

    Source: